Zibetti M, Merola A, Artusi C A, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L
Department of Neuroscience, University of Torino, Torino, Italy.
Eur J Neurol. 2014 Feb;21(2):312-8. doi: 10.1111/ene.12309. Epub 2013 Dec 7.
Levodopa/carbidopa intestinal gel (LCIG) infusion is nowadays becoming an established therapeutic option for advanced Parkinson's disease (PD) patients with fluctuating symptoms unresponsive to conventional oral treatment. As the implementation of LCIG therapy is increasing, there is a need for safety and efficacy data from current clinical practice.
All PD patients treated with LCIG at our centre over a 7-year period were analysed to determine the duration of treatment, retention rate, reasons for discontinuation, LCIG efficacy in motor complications, modifications of concomitant therapy and adverse events.
Of the 59 patients, seven subjects (12%) died of causes unrelated to LCIG infusion and 11 patients (19%) discontinued therapy prior to the cut-off date. Duodopa improved motor complications and over 90% of patients reported an improvement in their quality of life, autonomy and clinical global status. The most common adverse events were dislocation and kinking of the intestinal tube.
LCIG infusion is effective for the long-term treatment of advanced PD patients and exerts a positive and clinically significant effect on motor complications with a relatively low dropout rate.
左旋多巴/卡比多巴肠凝胶（LCIG）输注如今已成为晚期帕金森病（PD）患者的一种既定治疗选择，这些患者症状波动，对传统口服治疗无反应。随着LCIG治疗的应用日益增加，需要来自当前临床实践的安全性和有效性数据。
对我们中心7年内接受LCIG治疗的所有PD患者进行分析，以确定治疗持续时间、保留率、停药原因、LCIG在运动并发症方面的疗效、伴随治疗的调整以及不良事件。
59例患者中，7例（12%）死于与LCIG输注无关的原因，11例患者（19%）在截止日期前停止治疗。Duodopa改善了运动并发症，超过90%的患者报告生活质量、自主性和临床整体状况有所改善。最常见的不良事件是肠管移位和扭结。
LCIG输注对晚期PD患者的长期治疗有效，对运动并发症具有积极且临床上显著的效果，脱落率相对较低。
